Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 6Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Multiple Myeloma 2Lymphoma, Follicular 2Endometrial Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Solid Neoplasm 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatic Insufficiency 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Irinotecan 7Cyclophosphamide 7Vincristine 6Magnetic Resonance Spectroscopy 5Dactinomycin 5temsirolimus 4cixutumumab 4X-Rays 4Sirolimus 4Radiotherapy 4Phantoms, Imaging 4Etoposide 4Doxorubicin 4Specimen Handling 3Radiation 3Peripheral Blood Stem Cell Transplantation 3Nuclear Medicine Department, Hospital 3Melphalan 3Ifosfamide 3Gemcitabine 3Filgrastim 3ulixertinib 2tipifarnib 2thymoglobulin 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma × copanlisib × Clear all
NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡